GlassScriptPhysician profile
Jinny Caldentey
NPI 1871834788
$2,946.40
in general payments reported to CMS, 2019-2025
25 companies · $826 in 2025
The $826 reported for 2025 was more than what 93% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
See the full distribution for Hospice and Palliative Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $173 · 2021: $48.35 · 2022: $525 · 2023: $487 · 2024: $762 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $512.72 | 2021-2025 | Trelegy Ellipta, Nucala |
| Electromed, INC. | $273.03 | 2022-2025 | Smartvest |
| Baxter Healthcare | $224.84 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Metaneb System, Hillrom - Life 2000 Ventilation System |
| Medtronic, INC. | $214.58 | 2024 | Synchromedii |
| Amgen INC. | $203.49 | 2019-2025 | Otezla, Repatha, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.01 | 2019-2025 | Ofev, Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $165.06 | 2022-2025 | Zerbaxa, Capvaxive, Recarbrio |
| Inspire Medical Systems, INC. | $155.26 | 2023-2024 | Inspire |
| Genentech USA, INC. | $150.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $127.61 | 2022-2025 | Dupixent |
| Neurelis, INC. | $125.00 | 2025 | Valtoco |
| Genzyme Corporation | $89.11 | 2022 | |
| Verona Pharma, INC. | $63.58 | 2025 | Ohtuvayre |
| Currax Pharmaceuticals LLC | $61.08 | 2023-2025 | Contrave |
| Daiichi Sankyo INC. | $60.66 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $57.20 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $50.92 | 2019-2025 | |
| Lilly USA, LLC | $49.82 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $40.49 | 2022-2025 | |
| Sanofi Pasteur INC. | $30.15 | 2025 | |
| Viatris Specialty LLC | $29.40 | 2025 | Yupelri |
| Grifols USA, LLC | $23.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.77 | 2022 | |
| Advanced Respiratory, INC | $22.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinny Caldentey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.